Browse by ▼

Abbott Laboratories

  • The Best Healthcare Bet

    By Mohsin Saeed - June 18, 2013 | Tickers: ABT, BMY, GILD

    Gilead (NASDAQ: GILD) has been one of the most prolific investments in the healthcare sector. The company value has almost doubled in the last few years, and it continues to appreciate thanks to its stellar R&D. Gilead dominates the Hepatitis C Virus (HCV) treatment market, and the upcoming priority review of sofosbuvir can cement its HCV domination for years to come. It faces tough competition from Bristol Myers Squibb more »

  • Hedge Fund Brahman Capital Bets Big on This Pharma Stock

    By Meena Krishnamsetty - June 14, 2013 | Tickers: ABT, ENDP, GILD, PFE, TEVA

    A 13G filed with the SEC has disclosed that Brahman Capital, a hedge fund managed by Peter Hochfelder and his team, owns 6.3 million shares of Endo Health Solutions (NASDAQ: ENDP), a $4.3 billion market cap pharmaceutical company. We track quarterly 13F filings from hedge funds such as Brahman as part of our work researching investment strategies (we have found, for example, that the most popular small cap more »

  • Should You Buy This Dividend Aristocrat?

    By Timothy Green - June 14, 2013 | Tickers: ABT, MDT, SYK

    As the market becomes more volatile and high-grade dividend stocks begin to fall in price an opportunity opens up to buy those stocks at a more reasonable price than the last few months have offered. I recently introduced my Dividend Growth Watchlist, a list of dividend stocks with suggested buy targets, to make it simpler to track the prices of high-quality dividend stocks and determine when they become undervalued. Today more »

  • Identifying the Biggest Gem in Antares's Pipeline

    By Ali Yasar - June 13, 2013 | Tickers: ABT, ATRS, AUXL

    Following the publication of my article on the blockbuster potential of Antares Pharma's (NASDAQ: ATRS) transformational product (Otrexup), I have been inundated with reader requests to conduct a valuation study on another drug-device combination currently being advanced into clinic by Antares, i.e., Vibex QS-T, which is targeting the testosterone replacement therapy (TRT) market. 

    QS-T is being developed to administer testosterone using a subcutaneous (SC) injection route by patients more »

  • These Companies Have a Formula for Success

    By Mark Yagalla - June 12, 2013 | Tickers: ABT, DANOY.PK, MJN

    As populations grow and as food safety concerns increase, parents are being very selective about the infant baby formulas they buy. Infant formula is manufactured and designed for feeding of babies under 12 months of age.

    In China there is a very strong demand for brand-name baby formula after tainted formula from a Chinese manufacturer left 6 babies dead and over 300,000 suffering from adverse effects. The result is more »

  • Bet Big on Boomers and Babies

    By AnnaLisa Kraft - May 28, 2013 | Tickers: ABT, DANOY.PK, MJN

    With more baby boomers hitting retirement age and their babies starting families (the so-called Echo Boom) several stocks are bound to benefit. There are plenty of ways to play the greying generation, but far fewer that cover the space at the ends of the womb-to-tomb continuum...and even fewer that cover both ends. And I'm not talking diaper stocks.

    Best of breed plays

    In the next seventeen years the more »

  • 3 Pharma Companies to Buy in 2013

    By Shweta Dubey - May 28, 2013 | Tickers: ABT, ACT, CELG, TEVA

    Currently, a majority of pharma companies are facing the issue of generic competition. This has forced them to either expand their footprints in different geographical locations or prepare a better product pipeline. This will help these companies maintain their revenue streams once their patents on current top drugs expire.

    In this article, I have picked three such companies: Abbott Laboratories (NYSE: ABT), Celgene (NASDAQ: CELG), and Teva Pharmaceutical (NYSE: TEVAmore »)

  • Why This Stock Could Be a Smart Investment

    By Ashit Gulati - May 20, 2013 | Tickers: ABT, GE, UTX

    Over the past few years, General Electric (NYSE: GE)  has posted robust growth in several business divisions. The company expects to report a strong performance this year as well, especially in the healthcare division. Sales from this division have grown at a CAGR of 4.5% over the last three years. Going forward, based on GE's strong focus on research and innovation, I expect the company to continue reporting more »

  • Three Stocks that Offer Protection from Market Tantrums

    By Rupert Hargreaves - May 14, 2013 | Tickers: ABT, CLF, GIS, CB, KR

    The economy is only just starting to chug along again.  The situation in Europe is relatively unchanged, China is slowing down and banks are still de-leveraging. Yet stock markets are hitting all-time highs. With these mixed market messages, many investors and market commentators are confused about whether the market is overstretched or just warming up.

    Wherever we go from here, it is always handy to have stocks in your portfolio more »

  • 5 Stocks Loved By This Oregon-Based Fund

    By Meena Krishnamsetty - May 10, 2013 | Tickers: ABT, MSFT, OMC, ORCL, PEP

    This Lake Oswego, OR based fund seems to have a good appetite for technology stocks, with Oracle (NASDAQ: ORCL) and Microsoft (NASDAQ: MSFT) being its two major holdings. The management team at Jensen Investment has also made a massive addition to their stake in Abbott Laboratories (NYSE: ABT). Let us take a closer look into the fund's top 5 positions. You can also compare this portfolio with that of more »

  • Don’t Make Investing Too Complicated

    By Matthew Luke - May 10, 2013 | Tickers: ABT, ABBV, BEAM, CHD, MCD

    If I could send a message back in time to my younger self, I would only need to use four words, “Keep it simple, Stupid!” This is great advice for life in general, but especially good advice when investing one’s own money. How much better would my stock portfolio would look today if I had realized this when I first began investing!

    Sometimes we as investors can fall into more »

  • This New Drug Maker Still Has Upside Potential Left

    By Nick Chiu - May 9, 2013 | Tickers: ABT, ABBV, PFE

    AbbVie (NYSE: ABBV), formed in January this year following separation from Abbott Laboratories (NYSE: ABT), is a global, research-based pharmaceutical company with strong exposure to the immunology and cardiovascular diseases market.

    By spinning off its research-based pharmaceutical business, Abbott, a large-cap diversified healthcare company, now operates in four segments: diagnostics, medical devices, nutritionals, and generic pharmaceuticals. The nutrition segment is the main growth driver for Abbott, with a compound annual more »

  • The Ups and Downs of Diabetes

    By Tyler Wofford - May 8, 2013 | Tickers: ABT, MRK, NVO

    Recently, I have focused in on some companies that play a major role in diabetic's lives like mine. The financial implications of this disease are astounding, and have presented what seems to be a great opportunity for investors. Today, I will discuss the earnings results of some of the largest players involved with the disease. 

    Let's get the biggest surprise (to me) out of the way. I have more »

  • Are These Spin-Offs Investment Worthy?

    By Robert Ciura - May 6, 2013 | Tickers: ABT, ABBV, COP, PSX

    There have been a number of high-profile spin-offs over the past few years. Spin-offs, a form of divestiture in which a company will separate a subsidiary to form a separate and independent company, might catch investors by surprise. However, the newly separated businesses are often more rapidly growing than their former parent companies.

    Investors of the parent company receive shares in the spun-off businesses automatically, but as separate entities these more »

  • Abbott Shifts Focus to Nutrition Demand Overseas

    By Eileen Rojas - May 3, 2013 | Tickers: ABT, MJN, NSRGY

    Abbott Laboratories' (NYSE: ABT) first-quarter earnings were boosted by its nutritional product lines, which include baby formula Similac, adult drink Ensure, and Glucerna bars. In January 2013, the company decided to move away from branded pharmaceuticals, splitting the business into AbbVie(NYSE: ABBV) The company's focus has turned to the nutritional products market.

    The nutritional products sector is growing rather quickly, especially in emerging markets such as China and India. In more »

  • Building a Stronger Core With Abbott Laboratories

    By Justin Carley - April 30, 2013 | Tickers: ABT, ABBV, MJN, MDT, RHHBY

    It has been more than a 100 days since Abbott Laboratories (NYSE: ABT) separated its research-based pharmaceutical business into a newly formed entity named AbbVie (NYSE: ABBV). As is often the case, the spin-off has been the initial winner. AbbVie has produced a total return of more than 32% in pretty quick order. Abbott has done well, but the 17% return has clearly not kept pace. AbbVie is now a more »

  • You Don’t Have to Run a Cartel to Make Big Profits in Drugs

    By Ken McGaha - April 29, 2013 | Tickers: ABT, LLY, GSK, PFE, QCOR

    The market for prescription and over-the-counter drugs is huge and hugely profitable. With the global trend of an aging population well underway, it is nearly inevitable that demand for prescription and non-prescription drugs will rise. While much is made in the media regarding the so-called “patent cliff” faced by the large drug makers, well-placed investments now will allow investors to reap double-digit gains for years to come. Investors who are more »

  • Diabetes Isn't Good for Health, But It Can Be for Your Portfolio

    By Tyler Wofford - April 29, 2013 | Tickers: ABT, LLY, JNJ

    When I was six years old, something happened to me that I have never forgotten and will probably always live with. I couldn't eat without informing my parents exactly what I was eating, and had to have shots of insulin multiple times a day. Diabetes had busted in and turned my life around in a very short period of time.

    Within just a few years, I became well aware more »

  • When Others Are Fearful: Danone and Europe

    By Matthew Luke - April 28, 2013 | Tickers: ABT, GIS, DANOY.PK, MJN

    Berkshire Hathaway’s annual shareholder meeting is quickly approaching and I am reminded of Warren Buffett’s famous quote from 8 years ago: “Be fearful when others are greedy and greedy when others are fearful.” That second part is easier said than done, as it is extremely difficult to have the financial courage to run towards danger when everybody else is fleeing from it at full speed. But that kind more »

  • Can This New Drug Win Against Established Competitors?

    By Shas Dey - April 27, 2013 | Tickers: ABT, AMRN, GSK

    It’s not just about offering a better drug, but it’s also about launching it at the right time in the market. This is what I learned while studying about Amarin (NASDAQ: AMRN), which has a new drug out to cater to a vast number of patients in the cardiovascular realm. The phase III trial results have all been positive, yet, the presence of established competitors can leave some more »

  • Page 1 of 9